Zevra Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	122.29	106.47	23.61	27.46	10.46	28.65
Revenue Growth (YoY)	201.29%	350.92%	-14.02%	162.58%	-63.50%	115.61%
Cost of Revenue	17.03	16.48	7.42	2.17	0.34	2.06
Gross Profit	105.26	89.99	16.2	25.29	10.12	26.59
Selling, General & Admin	78.85	77.62	54.87	34.31	15.34	8.7
Depreciation & Amortization Expenses	2.56	3.86	6.24	0.77	-	-
Research & Development	13.88	12.74	42.1	39.81	37.28	10.16
Other Operating Expenses	58.71	58.71	-	-	-	-
Total Operating Expenses	154	152.93	103.2	74.89	52.62	18.86
Operating Income	-8.02	-62.94	-87	-49.6	-42.51	7.73
Interest Income	9.99	6.95	2.18	4.54	0.76	0.26
Interest Expense	-7.72	-7.98	-7.35	-1.5	-0.34	-0.38
Other Non-Operating Income (Expense)	179.88	150.65	2.04	0.52	-0.25	-16.14
Total Non-Operating Income (Expense)	182.15	149.62	-3.14	3.56	0.18	-16.25
Pretax Income	120.73	86.68	-90.14	-46.05	-42.33	-8.52
Provision for Income Taxes	-9.18	-3.45	-15.37	-	0.79	-0.03
Net Income	112.05	83.23	-105.51	-46.05	-41.54	-62.9
Net Income Attributable to Preferred Dividends	-	-	-	-	-	54.34
Net Income to Common	112.05	83.23	-105.51	-46.05	-41.54	-62.9
Shares Outstanding (Basic)	56	55	46	35	34	30
Shares Outstanding (Diluted)	58	57	46	35	34	30
Shares Change (YoY)	17.20%	23.81%	30.46%	2.79%	15.87%	647.71%
EPS (Basic)	2.05	1.40	-2.28	-1.30	-0.78	-2.11
EPS (Diluted)	1.99	1.35	-2.28	-1.30	-0.78	-2.11
Shares Outstanding	59.11	56.85	53.67	41.53	34.54	35.01
Free Cash Flow	12	-2.43	-69.67	-33.83	-18.81	10.34
Free Cash Flow Per Share	0.21	-0.04	-1.51	-0.95	-0.55	0.35
Gross Margin	86.07%	84.52%	68.59%	92.09%	96.72%	92.81%
Operating Margin	-6.56%	-59.12%	-368.47%	-180.63%	-406.44%	26.98%
Profit Margin	91.63%	78.17%	-446.85%	-167.69%	-397.24%	-29.86%
FCF Margin	9.81%	-2.29%	-295.04%	-123.20%	-179.86%	36.08%
EBITDA	-5.25	-58.89	-80.61	-48.6	-41.56	7.99
EBITDA Margin	-4.29%	-55.31%	-341.41%	-176.97%	-397.41%	27.87%
EBIT	-8.02	-62.94	-87	-49.6	-42.51	7.73
EBIT Margin	-6.56%	-59.12%	-368.47%	-180.63%	-406.44%	26.98%
Effective Tax Rate	-7.60%	-3.98%	17.05%	0.00%	-1.86%	0.40%

Updated May 6, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q